Abstract
Importance To examine the impact of SARS-CoV-2 vaccination of lactating mothers on human milk
Objective (1) To quantify SARS-CoV-2-specific immunoglobulin A (IgA) and immunoglobulin G (IgG) in human milk of lactating mothers who received the BNT162b2 vaccine, with reference to a cohort convalescent from antenatal COVID-19, and healthy lactating mothers. (2) To detect and quantify vaccine mRNA in human milk after BNT162b2 vaccination.
Design Gestational Immunity For Transfer 2 (GIFT-2) is a prospective cohort study of lactating mothers who were due to receive two doses of BNT162b2 vaccine, recruited between 5th February 2021 and 9th February 2021.
Setting Lactating healthcare workers living in Singapore
Participants Convenience sample of ten lactating healthcare workers. Human milk samples were collected at four time points: pre-vaccination, 1-3 days after dose one, 7-10 days after dose one, and 3-7 days after dose two of the BNT162b2 vaccine.
Exposure Two doses of the BNT162b2 vaccine 21 days apart.
Main Outcome and Measure (i) SARS-CoV-2-specific IgA and IgG in human milk of lactating mothers who received BNT162b2 vaccine, (ii) Detection and quantification of vaccine mRNA in human milk after BNT162b2 vaccination.
Results Ten lactating healthcare workers aged 32.5 years (range 29 – 42) were recruited, with 40 human milk samples collected and analysed. SARS-CoV-2-specific IgA was predominant in human milk of lactating mothers who received BNT162b2 vaccine. The sharpest rise in antibody production was 3 −7 days after dose two of the BNT162b2 vaccine, with medians of 1110 picomolar of anti-SARS-CoV-2 spike and 374 picomolar of anti-Receptor Binding Domain IgA. Vaccine mRNA was detected only on rare occasions, at a maximum concentration of 2 ng/mL.
Conclusions and Relevance In this cohort of ten lactating mothers following BNT162b2 vaccination, nine (90%) produced SARS-CoV-2 IgA, and ten (100%) produced IgG in human milk with minimal amounts of vaccine mRNA. Lactating individuals should continue breastfeeding in an uninterrupted manner after receiving mRNA vaccination for SARS-CoV-2.
Trial Registration Registered at clinicaltrials.gov (NCT04802278).
Question Does BNT162b2 (i) induce the production and secretion of SARS-CoV-2 specific antibodies into human milk, and/or (ii) get secreted into human milk?
Findings In this cohort that included ten lactating healthcare workers following BNT162b2 vaccination, 90% produced SARS-CoV-2 immunoglobulin A, and 100% produced immunoglobulin G in human milk, with minimal amounts of vaccine mRNA transfer.
Meaning Lactating individuals should continue breastfeeding in an uninterrupted manner after receiving SARS-CoV-2 mRNA vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04802278
Funding Statement
J.M. Low received funding from KTP_NUCMI and National University Health System Pitch for Funds to conduct this research. M.S.F. Ng is a recipient of the Career Development Award from the Agency for Science, Technology and Research, Singapore. L.W. Wang is a recipient of the National Medical Research Council Open Fund Young Investigator Research Grant (Project ID: MOH_000545_00) from the Ministry of Health, Singapore. This study is funded by the SARS-CoV-2 antibody initiative (R_571_000_081_213) and Reimagine research fund (R_571_001_093_114).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Healthcare Group (NHG) Domain Specific Review Board has approved this study "Gestational Immunity For Transfer GIFT-2: DSRB Reference Number: 2021/00095". The approval period is from 05 February 2021 to 04 February 2022. The NHG DSRB reference number for this study is 2021/00095.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript are available via correspondence.
